Literature DB >> 34953396

Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective.

Nafiseh Erfanian1, Afshin Derakhshani2, Saeed Nasseri3, Mohammad Fereidouni3, Behzad Baradaran4, Neda Jalili Tabrizi5, Oronzo Brunetti6, Renato Bernardini7, Nicola Silvestris8, Hossein Safarpour9.   

Abstract

Immunotherapy has revolutionized cancer treatment and brought new aspects into tumor immunology. Effective immunotherapy will require using the suitable target antigens, optimizing the interaction between the antigenic peptide, the APC, and the T cell, and the simultaneous inhibitor of the negative regulatory process that inhibits immunotherapeutic effects and develop resistance. Tumor heterogeneity and its microenvironment is the leading cause of resistance in patients. Recently by emerging the single-cell RNA sequencing technology and its combination with immunotherapy, now we can specifically evaluate the mechanism of tumors in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and other important processes. This review focuses on scRNA-seq, particularly on its application in cancer immunotherapy.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cancer; Immune checkpoints; Immunotherapy; ScRNA-seq

Mesh:

Substances:

Year:  2021        PMID: 34953396     DOI: 10.1016/j.biopha.2021.112558

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  1 in total

Review 1.  The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment.

Authors:  Hamidreza Hassanian; Zahra Asadzadeh; Amir Baghbanzadeh; Afshin Derakhshani; Antoine Dufour; Nazanin Rostami Khosroshahi; Souzan Najafi; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.